Chemotherapy News and Research

Latest Chemotherapy News and Research

US Oncology's PAPs help cancer patients to access high quality care

Through the continuous and tremendous growth of its patient assistance support program, US Oncology, Inc., a division of McKesson Corp. and a leading integrated oncology company, is helping cancer patients access the high quality cancer care they need. By helping patients obtain financial assistance, thousands can now afford much needed treatment and cancer therapies.

15 Feb 2011

Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

Oncolytics Biotech Inc. today announced preliminary results from a U.S. Phase 2 clinical trial (REO 017) using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar®) in patients with advanced pancreatic cancer. The trial is being conducted at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio (CTRC).

15 Feb 2011

Unmet need for medical help to address sexual issues in breast, gynecologic cancer survivors

Many women who survive breast and gynecologic cancers want medical help for their sexual issues, but most do not get it. A survey of hundreds of cancer survivors, published online in the journal Cancer, confirms that more than forty percent want medical attention for their sexual health needs.

15 Feb 2011

State court jury rules in favor of Merck in FOSAMAX trial

Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

15 Feb 2011

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer.

14 Feb 2011

Oestrogen reduces risk of breast cancer: Study

A team of researchers at CIC bioGUNE has revealed that oestrogen can reduce the risk of breast cancer. Their work shows that oestrogen is capable of reducing the number of breast cancer stem cells, which may explain the lower aggression of the tumour and, as a consequence, the possibility of a better prognosis.

14 Feb 2011

Study: Leptin resistance may help prevent ARDS, ALI development in patients with type II diabetes

Resistance to leptin, a protein that plays a key role in regulating metabolism and appetite, may help prevent the development of acute respiratory distress syndrome and acute lung injury in individuals with type II diabetes, according to a study conducted by researchers in Chicago.

13 Feb 2011

Genes for prostate cancer mapped for the first time

A genetic blue print that uncovers many of the mutations and genetic damage that drives prostate cancer and could lead to new treatments and better diagnosis has been found. This would mean earlier detection and new breeds of drugs to reverse the damage. Also each patient could have his own “cancer chart” made so that his treatment is personalized. The study, conducted by researchers from the Broad Institute, Dana-Farber Cancer Institute and Weill Cornell Medical College, appears in the Feb. 10 issue of Nature.

13 Feb 2011

Study finds too low drug concentrations used for treatment of children with TB

The realization of medically treating different children uniquely may start with one of the deadliest diseases in existence: tuberculosis.

11 Feb 2011

Scientists develop novel treatment strategy for multiple myeloma

Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The study's findings, published in today's edition of the journal "Blood," are the first to demonstrate the synergistic, anti-myeloma effects of this combination regimen both in vitro and in vivo.

11 Feb 2011

Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer. Tesetaxel, the leading oral taxane in clinical development, will be evaluated for its use as both first- and second-line chemotherapy.

10 Feb 2011

Indiana University creates Institute for Personalized Medicine

Indiana University has announced a major commitment to research in one of health care's most promising fields with the creation of the Indiana Institute for Personalized Medicine.

10 Feb 2011

Study: 30% of older patients with vulvar cancer die from treatment complications, ICD

Research by the American Academy of Family Physicians demonstrates that vulvar cancer occurs most frequently in women age 65 to 75 years of age. Thirty percent of patients with vulvar cancer are age 70 or older, and the rate increases with age, reaching a peak of 20 per 100,000 women by 75 years of age.

10 Feb 2011

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).

10 Feb 2011

Breakthrough in cancer research can help reduce heart failure, increase survival rates

A breakthrough by scientists at Queen's University Belfast could help reduce heart failure in cancer patients around the world, and ultimately increase survival rates.

10 Feb 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

DiaTech, Walter Reed collaborate to determine the best chemotherapy for cancer

DiaTech Oncology announced today they have engaged in a pilot with Walter Reed Army Medical Center to determine the best Chemotherapy for Cancer patients. Medical and GYN Oncologists and from Walter Reed have been working with DiaTech Oncology (Nashville, TN) using the MiCK assay for apoptosis in order to give physicians a tool that can predict the best chemotherapy pathway in treating cancer patients.

9 Feb 2011

A.P. Pharma provides update on response to APF530 Complete Response Letter

A.P. Pharma, Inc., a specialty pharmaceutical company, today provided an update on its progress toward responding to the Complete Response Letter for APF530 that the Company received from the U.S. Food and Drug Administration (FDA) in March 2010.

9 Feb 2011

Study finds breast cancer patients do not benefit from axillary lymph node dissection

Among patients with early-stage breast cancer that had spread to a nearby lymph node and who received treatment that included lumpectomy and radiation therapy, women who just had the sentinel lymph node removed did not have worse survival than women who had more extensive axillary lymph node dissection, according to a study in the February 9 issue of JAMA.

9 Feb 2011

Aushon BioSystems enters diagnostic development collaboration with Peking University Cancer Hospital

Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services announced that it has signed a letter of intent to enter into a diagnostic development collaboration with Peking University Cancer Hospital ("PUCH"), Beijing, China.

9 Feb 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

US Oncology's PAPs help cancer patients to access high quality care

Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

Unmet need for medical help to address sexual issues in breast, gynecologic cancer survivors

State court jury rules in favor of Merck in FOSAMAX trial

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

Oestrogen reduces risk of breast cancer: Study

Study: Leptin resistance may help prevent ARDS, ALI development in patients with type II diabetes

Genes for prostate cancer mapped for the first time

Study finds too low drug concentrations used for treatment of children with TB

Scientists develop novel treatment strategy for multiple myeloma

Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer

Indiana University creates Institute for Personalized Medicine

Study: 30% of older patients with vulvar cancer die from treatment complications, ICD

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

Breakthrough in cancer research can help reduce heart failure, increase survival rates

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

DiaTech, Walter Reed collaborate to determine the best chemotherapy for cancer

A.P. Pharma provides update on response to APF530 Complete Response Letter

Study finds breast cancer patients do not benefit from axillary lymph node dissection

Aushon BioSystems enters diagnostic development collaboration with Peking University Cancer Hospital

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in